"Pro firmu Farmak, a.s. bylo realizov\u00E1no studium krystalov\u00E9 struktury dodan\u00FDch nov\u00FDch farmaceutick\u00FDch p\u0159\u00EDpravk\u016F, v\u010Detn\u011B v\u00FDvoje a optimalizace m\u011B\u0159\u00EDc\u00EDch postup\u016F; vyhodnocen\u00ED \u010Distoty API na z\u00E1klad\u011B zm\u011B\u0159en\u00FDch RTG difrak\u010Dn\u00EDch z\u00E1znam\u016F a porovn\u00E1n\u00ED s patentovan\u00FDmi l\u00E1tkami. Firmou Farmak, a.s. bylo dod\u00E1no 141 pr\u00E1\u0161kov\u00FDch vzork\u016F API v\u010Detn\u011B p\u0159\u00EDslu\u0161n\u00FDch pracovn\u00EDch standard\u016F (jednalo o 10 krystalografick\u00FDch typ\u016F r\u016Fzn\u00FDch organick\u00FDch l\u00E1tek), kter\u00E9 byly analyzov\u00E1ny pomoc\u00ED RTG pr\u00E1\u0161kov\u00E9 difrakce a vyhodnocen\u00ED bylo \u0159e\u0161eno pomoc\u00ED software HighScore Plus (PANanlytical B.V.). Pro optimalizaci kvantitativn\u00ED f\u00E1zov\u00E9 anal\u00FDzy byly aplikov\u00E1ny metody vnit\u0159n\u00EDho standardu a standardn\u00EDho p\u0159\u00EDdavku; nov\u00E9 l\u00E1tky byly porovn\u00E1v\u00E1ny s p\u0159\u00EDslu\u0161n\u00FDmi patenty pro vylou\u010Den\u00ED shody a byla \u0159e\u0161ena krystalov\u00E1 struktura pro n\u00E1slednou pr\u00E1vn\u00ED ochranu nov\u00FDch l\u00E1tek. U vybran\u00FDch l\u00E1tek byl sledov\u00E1n vliv p\u0159\u00EDpravy na velikost specifick\u00E9 plochy povrchu m\u011B\u0159en\u00E9 fyzisorpc\u00ED kombinace r\u016Fzn\u00FDch plyn\u016F a r\u016Fzn\u00E9 teploty." . . "Pro firmu Farmak, a.s. bylo realizov\u00E1no studium krystalov\u00E9 struktury dodan\u00FDch nov\u00FDch farmaceutick\u00FDch p\u0159\u00EDpravk\u016F, v\u010Detn\u011B v\u00FDvoje a optimalizace m\u011B\u0159\u00EDc\u00EDch postup\u016F; vyhodnocen\u00ED \u010Distoty API na z\u00E1klad\u011B zm\u011B\u0159en\u00FDch RTG difrak\u010Dn\u00EDch z\u00E1znam\u016F a porovn\u00E1n\u00ED s patentovan\u00FDmi l\u00E1tkami. Firmou Farmak, a.s. bylo dod\u00E1no 141 pr\u00E1\u0161kov\u00FDch vzork\u016F API v\u010Detn\u011B p\u0159\u00EDslu\u0161n\u00FDch pracovn\u00EDch standard\u016F (jednalo o 10 krystalografick\u00FDch typ\u016F r\u016Fzn\u00FDch organick\u00FDch l\u00E1tek), kter\u00E9 byly analyzov\u00E1ny pomoc\u00ED RTG pr\u00E1\u0161kov\u00E9 difrakce a vyhodnocen\u00ED bylo \u0159e\u0161eno pomoc\u00ED software HighScore Plus (PANanlytical B.V.). Pro optimalizaci kvantitativn\u00ED f\u00E1zov\u00E9 anal\u00FDzy byly aplikov\u00E1ny metody vnit\u0159n\u00EDho standardu a standardn\u00EDho p\u0159\u00EDdavku; nov\u00E9 l\u00E1tky byly porovn\u00E1v\u00E1ny s p\u0159\u00EDslu\u0161n\u00FDmi patenty pro vylou\u010Den\u00ED shody a byla \u0159e\u0161ena krystalov\u00E1 struktura pro n\u00E1slednou pr\u00E1vn\u00ED ochranu nov\u00FDch l\u00E1tek. U vybran\u00FDch l\u00E1tek byl sledov\u00E1n vliv p\u0159\u00EDpravy na velikost specifick\u00E9 plochy povrchu m\u011B\u0159en\u00E9 fyzisorpc\u00ED kombinace r\u016Fzn\u00FDch plyn\u016F a r\u016Fzn\u00E9 teploty."@cs . "Determination of crystal structure and specific surface area of pharmaceutical substances and evaluation of API purity on the basis of measured X-ray diffraction notes and sorption of gases."@en . . "Filip, Jan" . "52153" . "Ur\u010Den\u00ED krystalov\u00E9 struktury a plochy specifick\u00E9ho povrchu farmaceutick\u00FDch p\u0159\u00EDpravk\u016F a vyhodnocen\u00ED \u010Distoty API na z\u00E1klad\u011B zm\u011B\u0159en\u00FDch RTG difrak\u010Dn\u00EDch z\u00E1znam\u016F a sorpce plyn\u016F" . "crystal structure, X-ray powder diffraction, active pharmaceutical substances"@en . . . "RIV/61989592:15310/14:33152775!RIV15-MSM-15310___" . "RIV/61989592:15310/14:33152775" . . "Determination of crystal structure and specific surface area of pharmaceutical substances and evaluation of API purity on the basis of measured X-ray diffraction notes and sorption of gases."@en . . "Ur\u010Den\u00ED krystalov\u00E9 struktury a plochy specifick\u00E9ho povrchu farmaceutick\u00FDch p\u0159\u00EDpravk\u016F a vyhodnocen\u00ED \u010Distoty API na z\u00E1klad\u011B zm\u011B\u0159en\u00FDch RTG difrak\u010Dn\u00EDch z\u00E1znam\u016F a sorpce plyn\u016F"@cs . . "Ur\u010Den\u00ED krystalov\u00E9 struktury a plochy specifick\u00E9ho povrchu farmaceutick\u00FDch p\u0159\u00EDpravk\u016F a vyhodnocen\u00ED \u010Distoty API na z\u00E1klad\u011B zm\u011B\u0159en\u00FDch RTG difrak\u010Dn\u00EDch z\u00E1znam\u016F a sorpce plyn\u016F" . "15310" . . . "Ur\u010Den\u00ED krystalov\u00E9 struktury a plochy specifick\u00E9ho povrchu farmaceutick\u00FDch p\u0159\u00EDpravk\u016F a vyhodnocen\u00ED \u010Distoty API na z\u00E1klad\u011B zm\u011B\u0159en\u00FDch RTG difrak\u010Dn\u00EDch z\u00E1znam\u016F a sorpce plyn\u016F"@cs . . . "N" . "Aparicio Ordonez, Claudia Jeannette Sarita" . "2"^^ . "3"^^ . "[10EB963FAFC7]" . "Study of crystal structure of given new pharmaceutical substances was realized for firm Farmak,a.s.including development and optimalisation of measuring procedures, evaluation of API purity on the basis of measured X-ray diffraction and comparison with patented substances. Farmak a.s. delivered 141 powdered samples API including working standards ( 10 crystal types of different organic substances), which were analysed by X-ray powder diffraction and evaluation was solved by software HighScore Plus (PANanlytical B.V). For optimalisation of qantitative analysis were applied methods of inside standard and standard addition. New substances were compared with relevant patents for exclusion parity and crystal structure was solved for subsequent legal protection of the new substances.Observation of preparation influence on size of specific surface area measured by physiosorption of combination of different gases and different temperatures was also applied on some substances."@en . "3"^^ . . "RCPTM-3725/FARMAK-2014-01" . "Ka\u0161l\u00EDk, Josef" . . "Aparicio Ordonez, Claudia Jeannette Sarita" . "Farmak a.s." . . .